The approval makes COPD the sixth indication for the blockbuster treatment and makes Dupixent the first available biologic for the condition. As per a 27 September press announcement, Dupixent ...

The approval makes COPD the sixth indication for the blockbuster treatment and makes Dupixent the first available biologic for the condition. As per a 27 September press announcement, Dupixent will be ...

Conclusion. In the treatment of COPD exacerbations, systemic corticosteroids improve airflow limitations, decrease treatment failure rates, decrease the risk of relapse, and may improve symptoms ...

Researchers from Teesside University and the National Institute for Health and Care Research (NIHR) Applied Research ...

Inhalers for chronic obstructive pulmonary disease (COPD) are a mainstay of treatment. These medications are inhaled through your mouth so they can directly reach your lungs. If your healthcare ...

and Sanofi SA, could mean another $6.4 billion-plus in sales by the end of the decade. Regulators cleared the drug as an add-on maintenance treatment for chronic obstructive pulmonary disease (COPD) ...

The Spanish COPD guidelines recommend treatment of the mixed COPD–asthma phenotype with ICS and a long-acting bronchodilator (LABD) as a first option to improve lung function, respiratory ...

After 12 weeks of nebulized NAC, patients’ mean phlegm scores, as measured by the COPD assessment test, significantly decreased from 3.47 at baseline to 2.62. N-acetylcysteine (NAC) nebulizer ...

Verona's ensifentrine will be a 'paradigm shift in COPD treatment,' GlobalData says Nucala made its debut in 2015 with an FDA approval for severe asthma. Since then, the antibody has racked up a ...